Targeting Gli transcription activation by small molecule suppresses tumor growth

被引:0
|
作者
G Bosco-Clément
F Zhang
Z Chen
H-M Zhou
H Li
I Mikami
T Hirata
A Yagui-Beltran
N Lui
H T Do
T Cheng
H-H Tseng
H Choi
L-T Fang
I-J Kim
D Yue
C Wang
Q Zheng
N Fujii
M Mann
D M Jablons
B He
机构
[1] Thoracic Oncology Program,Department of Surgery
[2] Helen Diller Family Comprehensive Cancer Center,Division of Life and Health Sciences
[3] University of California San Francisco,Department of Surgery, Division of Thoracic Surgery
[4] Tsinghua University Graduate School at Shenzhen,Department of Lung Cancer
[5] School of Life Sciences,Department of Chemical Biology and Therapeutics
[6] Tsinghua University,Division of Cardiothoracic Surgery, Department of Surgery
[7] Nippon Medical School,undefined
[8] Tianjin Medical University Cancer Institute and Hospital,undefined
[9] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education),undefined
[10] Thoracic Surgery II,undefined
[11] Peking University Cancer Hospital and Institute,undefined
[12] St Jude Children’s Research Hospital,undefined
[13] University of California,undefined
来源
Oncogene | 2014年 / 33卷
关键词
cancer; targeted therapy; Gli; TAF9; Hedgehog pathway;
D O I
暂无
中图分类号
学科分类号
摘要
Targeted inhibition of Hedgehog signaling at the cell membrane has been associated with anticancer activity in preclinical and early clinical studies. Hedgehog signaling involves activation of Gli transcription factors that can also be induced by alternative pathways. In this study, we identified an interaction between Gli proteins and a transcription coactivator TBP-associated factor 9 (TAF9), and validated its functional relevance in regulating Gli transactivation. We also describe a novel, synthetic small molecule, FN1-8, that efficiently interferes with Gli/TAF9 interaction and downregulate Gli/TAF9-dependent transcriptional activity. More importantly, FN1-8 suppresses cancer cell proliferation in vitro and inhibits tumor growth in vivo. Our results suggest that blocking Gli transactivation, an important control point of multiple oncogenic pathways, may be an effective anticancer strategy.
引用
收藏
页码:2087 / 2097
页数:10
相关论文
共 50 条
  • [41] Activation Instead of Inhibition: Targeting Proenzymes for Small-Molecule Intervention
    Ottmann, Christian
    Hauske, Patrick
    Kaiser, Markus
    CHEMBIOCHEM, 2010, 11 (05) : 637 - 639
  • [42] Small molecule activation of the LKB1 tumor suppressor
    Mitchell, Dominique C.
    Liu, Jin
    Wang, Zheng
    He, Changliang
    Ding, Luo
    Adler, Marc
    Wang, LeeAnn L.
    Keith, Aidan
    Hwang, Y. Christina
    Tsui, Tsz Kin M.
    Ramamoorthi, Roopa
    Lively, Sarah
    Drakas, Robert A.
    Ramani, Vijay
    Verba, Kliment A.
    Qing, Tingting
    Beresis, Richard T.
    Gordan, John D.
    CANCER RESEARCH, 2020, 80 (16)
  • [43] An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer
    Ushijima, Miho
    Shiota, Masaki
    Matsumoto, Takashi
    Kashiwagi, Eiji
    Inokuchi, Junichi
    Eto, Masatoshi
    CANCER SCIENCE, 2022, 113 (05) : 1731 - 1738
  • [44] Characterization of a novel small molecule antagonist of 6-phosphofructo-2-kinase that suppresses glucose metabolism and tumor growth
    Clem, Brian
    Tapolsky, Gilles H.
    O'Neal, Julie
    Chand, Pooran
    Clem, Amy
    Trent, John
    Telang, Sucheta
    Chesney, Jason
    CANCER RESEARCH, 2011, 71
  • [45] VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo
    Elizabeth A Harrington
    David Bebbington
    Jeff Moore
    Richele K Rasmussen
    Abi O Ajose-Adeogun
    Tomoko Nakayama
    Joanne A Graham
    Cecile Demur
    Thierry Hercend
    Anita Diu-Hercend
    Michael Su
    Julian M C Golec
    Karen M Miller
    Nature Medicine, 2004, 10 : 262 - 267
  • [46] Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth
    Clem, Brian
    Telang, Sucheta
    Clem, Amy
    Yalcin, Abdullah
    Meier, Jason
    Simmons, Alan
    Rasku, Mary Ann
    Arumugam, Sengodagounder
    Dean, William L.
    Eaton, John
    Lane, Andrew
    Trent, John O.
    Chesney, Jason
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (01) : 110 - 120
  • [47] AN ORAL FIRST-IN-CLASS SMALL MOLECULE RSK INHIBITOR SUPPRESSES AR VARIANTS AND TUMOR GROWTH IN PROSTATE CANCER
    Shiota, Masaki
    Ushijima, Miho
    Matsumoto, Takashi
    Kashiwagi, Eiji
    Inokuchi, Junichi
    Eto, Masatoshi
    JOURNAL OF UROLOGY, 2022, 207 (05): : E98 - E99
  • [48] VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo
    Harrington, EA
    Bebbington, D
    Moore, J
    Rasmussen, RK
    Ajose-Adeogun, AO
    Nakayama, T
    Graham, JA
    Demur, C
    Hercend, T
    Diu-Hercend, A
    Su, M
    Golec, JMC
    Miller, KM
    NATURE MEDICINE, 2004, 10 (03) : 262 - 267
  • [49] Metformin suppresses small intestinal neuroendocrine tumor growth in vivo
    Barazeghi, E.
    Axling, F.
    Hellman, P.
    Norlen, O.
    Stalberg, P.
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 19 - 19
  • [50] Combining a protein-targeting small molecule and a thiol-targeting small molecule for detecting a serum risk marker of liver tumor recurrence
    Cheng, Wenting
    Wang, Huali
    Zhao, Guiping
    Adeel, Khan
    Zhang, Jianchun
    Li, Jinlong
    TALANTA, 2023, 263